Sulfonamide derivatives as bradykinin antagonists

A compound of formula (I)

• wherein
• R1 is selected from hydrogen atom and C1-C4 alkyl group;
• R2 is selected from (1) hydrogen atom;
• with the proviso that R1 and R2 can not be simultaneously hydrogen atom;
• (2) —(CH2)n—NRaRb, and, (3) —(CH2)m—X-Q, or
• R1 and R2 together with the nitrogen atom to which they are attached form a 4-7 membered heterocyclic ring containing 0-3 heteroatom (in addition to the nitrogen atom to which R1 and R2 attached) selected from O, S and N;
• wherein said ring is optionally substituted with C1-C4 alkyl, —(CH2)q—Y—P, oxo, 4-(4,5-dihydro-1H-imidazol-2-yl)-benzyl, 4-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-benzyl or 4-ylmethyl-benzamidine group;
• R3, R4 and R5 are independently of each other selected from hydrogen atom, halogen atom, cyano, amino, and amino substituted with one or more C1-C4 alkyl group, C1-C4 alkoxy, trifluoromethyl, trifluoromethoxy, C1-C4 alkyl, hydroxy, C1-C4 alkoxycarbonyl or —C(═O)—NH2 group;
• Z is selected from (1) single bond;
• (2) oxygen atom;
• (3) CH2 group;
• (4) CO group;
• (5) NRc group;
• (6) S atom;
• and (7) SO2 group;
• n is an integer from 1 to 4;
• m is 0 or an integer from 2 to 6;
• q is an integer from 0 to 4;
• Ra and Rb are independently from each other selected from (1) hydrogen atom and (2) C1-C6 alkyl group, said C1-C6 alkyl group is straight or branched;
• Rc is selected from hydrogen atom and C1-C4 alkyl group;
• X is selected from a single bond, —CO—, —CO—NH—, and —NH—CO— group;
• Y is selected from a single bond, —CO—, and —CONRa group;
• P is selected from (1) —N(C1-C4 alkyl)2 group;
• (2) —NH—(CH2)n-Het group;
• (3) a 4-7 membered ring containing 1-3 heteroatom selected from O, S and N;
• said 4-7 membered ring is saturated, partially unsaturated or aromatic, and said 4-7 membered ring is optionally substituted with oxo or C1-C4 alkyl group;
• Q is selected from (1) a 4-7 membered ring containing 1-3 heteroatom selected from O, S and N;
• said 4-7 membered ring is saturated, partially unsaturated or aromatic, and said 4-7 membered ring is optionally substituted with oxo, —(CH2)n-Het, 1-piperidinyl, 1-(C1-C4-alkyl)-4-piperidinyl, 4-piperidinyl, 2-pyrimidinyl, 2-pyrazinyl, 2-pyridyl, 4-methyl-2-pyridyl, 6-methyl-2-pyridyl or 4-pyridyl group;
• (2) phenyl group, optionally substituted with —(CH2)n-Het, —(CH2)n—NH—C(═NH)—NH2, 4,5-dihydro-1H-imidazol-2-yl or [1,4′]bipiperidinyl-1′-yl group;
• (3) C5-C7 cycloalkyl group, optionally substituted with —(CH2)n-Het group;
• (4) benzyl group, optionally substituted with —(CH2)n-Het, —(CH2)n—NH—C(═NH)—NH2 or 4,5-dihydro-1H-imidazol-2-yl group;
• and (5) —(CH2)n-Het group;
• and,
• Het is a 4-7 membered heterocyclic ring containing 1-3 heteroatom selected from O, S, SO2 and N, optionally substituted with (1) oxo;
• or (2) one or more C1-C4 alkyl group.